Swedish Rectal Cancer Trial Findings
The Swedish Rectal Cancer Trial demonstrated that preoperative short-course radiotherapy (25 Gy in 5 fractions over 1 week) followed by surgery within 1 week significantly improved overall survival, cancer-specific survival, and local recurrence rates compared to surgery alone in resectable rectal cancer. 1
Key Trial Results
The landmark trial randomized 1,168 patients between 1987-1990, with long-term follow-up showing:
- Overall survival: 58% at 5 years with preoperative RT vs 48% with surgery alone (P=0.004) 1
- Cancer-specific survival: 74% at 9 years vs 65% (P=0.002) 2
- Local recurrence: 9% vs 26% at 13-year follow-up (P<0.001) 2
The survival benefit persisted at 13-year median follow-up, with overall survival of 38% in the irradiated group versus 30% in controls (P=0.008) 2. Importantly, the reduction in local recurrence was observed at all tumor heights, though not statistically significant for tumors >10 cm from the anal verge 2.
Current Recommended Preoperative Radiotherapy Regimens
Based on contemporary guidelines, two preoperative radiotherapy approaches are recommended 3:
Short-Course Radiotherapy (SCRT)
- Dose: 25 Gy in 5 fractions of 5 Gy each over 1 week 4, 3
- Surgery timing: Within 7 days from completion, ideally 0-3 days if patient ≤75 years (<10 days from first fraction) 3, 5
- Indications: Intermediate-risk rectal cancers (most cT3 with MRF-, cT2 very low, N1-2, EMVI+, limited cT4aN0) 3
Long-Course Chemoradiotherapy
- Dose: 45-50.4 Gy in 1.8-2 Gy fractions over 5-6 weeks 4, 3
- Concurrent chemotherapy: 5-fluorouracil (continuous infusion preferred over bolus) or oral capecitabine 3, 5
- Surgery timing: 5-12 weeks after completion 4
- Indications: Locally advanced disease (cT3 MRF+, cT4a/b, lateral node+) 3
Preoperative treatment is strongly preferred over postoperative treatment because it is more effective and less toxic 3, 6.
Adjuvant Chemotherapy Recommendations
For stage II-III rectal cancer, current guidelines emphasize total neoadjuvant therapy (TNT) as the preferred approach, which includes both chemotherapy and radiotherapy before surgery 7, 8:
TNT Regimens
- Short-course RT followed by consolidation chemotherapy: CAPEOX or FOLFOX for 4-6 cycles before surgery 7, 8
- Induction chemotherapy followed by chemoradiotherapy: FOLFIRINOX followed by long-course chemoRT 7
Important caveat: Recent 5-year data from the RAPIDO trial showed that preoperative short-course RT in TNT may be associated with higher local recurrence rates (10% vs 6%, P=0.027) compared to standard chemoRT 8. This must be weighed against improved disease-free survival and pathologic complete response rates.
Traditional Adjuvant Chemotherapy (if not using TNT)
- Regimen: FOLFOX or CAPEOX for 4-6 months postoperatively 9
- Indication: Stage III disease or high-risk stage II 10
- Evidence: Meta-analysis showed 17% reduction in death risk (HR=0.83, CI: 0.76-0.91) and 25% reduction in recurrence risk (HR=0.75, CI: 0.68-0.83) with adjuvant chemotherapy 10
Critical Implementation Points
The Swedish trial's success required specific technical considerations that remain relevant:
- Volume reduction is crucial: The Stockholm I trial showed increased postoperative mortality in elderly patients (>75 years) with large pelvic/mesenteric volumes, but Stockholm II eliminated this risk by reducing to posterior pelvis only 11
- Quality surgery matters: Total mesorectal excision (TME) is mandatory and must be performed with intact mesorectal fascia 3, 5
- Timing is critical: For SCRT, immediate surgery (<10 days) is essential to achieve the trial's results 3, 5
Common pitfall: Delivering 5×5 Gy with delayed surgery (>2 weeks) represents a different treatment paradigm than the original Swedish trial, though this approach is now used intentionally in elderly/unfit patients or for tumor downstaging 3.
The evidence strongly supports that preoperative radiotherapy at biologically effective doses ≥30 Gy reduces local recurrence by 50-70% and improves survival by approximately 10% 12, 13.